Clinical trial
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in…
NCT00084318 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00084318 |
|---|---|
| Title | Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck |
| Official title | A Phase II Randomized Trial Of Surgery Followed By Chemoradiotherapy Plus Cetuximab For Advanced Squamous Cell Carcinoma Of The Head and Neck |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH NRG Oncology |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Drug, Radiation |
| Interventions | cetuximab, cisplatin, docetaxel, radiation therapy |
| Enrollment | 238 |
| Start date | Apr 1, 2004 |
| Primary completion | Mar 1, 2009 |
| Completion | Dec 1, 2016 |
| First posted | Jun 11, 2004 |
| Last update posted | Dec 12, 2018 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: